Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD

Autor Buhl, Roland, Banerji, Donald
Vydáno 2012

Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study

Autor Kulich, Károly, Keininger, Dorothy L, Tiplady, Brian, Banerji, Donald
Vydáno v Int J Chron Obstruct Pulmon Dis (2015)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study

Autor Dahl, Ronald, Jadayel, Dalal, Alagappan, Vijay KT, Chen, Hungta, Banerji, Donald
Vydáno 2013

Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study

Autor Hashimoto, Shu, Ikeuchi, Hisataro, Murata, Shujiro, Kitawaki, Tetsuji, Ikeda, Kimitoshi, Banerji, Donald
Vydáno v Int J Chron Obstruct Pulmon Dis (2016)

A novel model-based approach for dose determination of glycopyrronium bromide in COPD

Autor Arievich, Helen, Overend, Tim, Renard, Didier, Gibbs, Michael, Alagappan, Vijay, Looby, Michael, Banerji, Donald
Vydáno 2012

QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Stud...

Autor Chapman, Kenneth R., Bateman, Eric D., Chen, Hungta, Hu, Hulin, Fogel, Robert, Banerji, Donald
Vydáno v Chronic Obstr Pulm Dis (2015)

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

Autor Bateman, Eric D., Ferguson, Gary T., Barnes, Neil, Gallagher, Nicola, Green, Yulia, Henley, Michelle, Banerji, Donald
Vydáno 2013

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

Autor Kerwin, Edward, Hébert, Jacques, Gallagher, Nicola, Martin, Carmen, Overend, Tim, Alagappan, Vijay K.T., Lu, Yimeng, Banerji, Donald
Vydáno 2012

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis

Autor Vogelmeier, Claus, Zhong, Nanshan, Humphries, Michael J, Mezzi, Karen, Fogel, Robert, Bader, Giovanni, Patalano, Francesco, Banerji, Donald
Vydáno v Int J Chron Obstruct Pulmon Dis (2016)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

Autor Wedzicha, Jadwiga A, Zhong, Nanshan, Ichinose, Masakazu, Humphries, Michael, Fogel, Robert, Thach, Chau, Patalano, Francesco, Banerji, Donald
Vydáno v Int J Chron Obstruct Pulmon Dis (2017)

Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study

Autor Ferguson, Gary T., Taylor, Angel Fowler, Thach, Chau, Wang, Qian, Schubert-Tennigkeit, Agnes A., Patalano, Francesco, Banerji, Donald
Vydáno v Chronic Obstr Pulm Dis (2016)

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

Autor Zhong, Nanshan, Wang, Changzheng, Zhou, Xiangdong, Zhang, Nuofu, Humphries, Michael, Wang, Linda, Thach, Chau, Patalano, Francesco, Banerji, Donald
Vydáno v Int J Chron Obstruct Pulmon Dis (2015)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD

Autor Anzueto, Antonio R, Vogelmeier, Claus F, Kostikas, Konstantinos, Mezzi, Karen, Fucile, Sebastian, Bader, Giovanni, Shen, Steven, Banerji, Donald, Fogel, Robert
Vydáno v Int J Chron Obstruct Pulmon Dis (2017)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

Autor Anzueto, Antonio R., Kostikas, Konstantinos, Mezzi, Karen, Shen, Steven, Larbig, Michael, Patalano, Francesco, Fogel, Robert, Banerji, Donald, Wedzicha, Jadwiga A.
Vydáno v Respir Res (2018)

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

Autor D'Urzo, Anthony, Ferguson, Gary T, van Noord, Jan A, Hirata, Kazuto, Martin, Carmen, Horton, Rachael, Lu, Yimeng, Banerji, Donald, Overend, Tim
Vydáno 2011

Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study

Autor Mackay, Alexander J., Kostikas, Konstantinos, Roche, Nicolas, Frent, Stefan-Marian, Olsson, Petter, Pfister, Pascal, Gupta, Pritam, Patalano, Francesco, Banerji, Donald, Wedzicha, Jadwiga A.
Vydáno v Respir Res (2020)

Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients

Autor Kostikas, Konstantinos, Mackay, Alexander J, Vogelmeier, Claus F, Frent, Stefan-Marian, Gupta, Pritam, Banerji, Donald, Patalano, Francesco, Pfister, Pascal J, Wedzicha, Jadwiga A
Vydáno v Int J Chron Obstruct Pulmon Dis (2020)

Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME

Autor Frent, Stefan M., Chapman, Kenneth R., Larbig, Michael, Mackay, Alexander, Fogel, Robert, Gutzwiller, Florian S., Shen, Steven, Patalano, Francesco, Banerji, Donald, Kostikas, Konstantinos, Wedzicha, Jadwiga A.
Vydáno v Am J Respir Crit Care Med (2019)

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study

Autor Vogelmeier, Claus F, Chapman, Kenneth R, Miravitlles, Marc, Roche, Nicolas, Vestbo, Jørgen, Thach, Chau, Banerji, Donald, Fogel, Robert, Patalano, Francesco, Olsson, Petter, Kostikas, Konstantinos, Wedzicha, Jadwiga A
Vydáno v Int J Chron Obstruct Pulmon Dis (2018)